Latest AMRX reports update at 2024-05-08: 2024-Q12023-Q1
Amneal Pharmaceuticals logo
Amneal Pharmaceuticals AMRX
$ 5.91 2.6%

Amneal Pharmaceuticals Financial Statements 2011-2024 | AMRX

Annual Financial Statements Amneal Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.04 B 290 M 660 M 709 M 613 M 1.52 B - - - - - - -

Shares

176 M 151 M 149 M 147 M 132 M 127 M - - - - - - -

Historical Prices

5.91 1.92 4.43 4.81 4.49 12.3 - - - - - - -

Net Income

-79.3 M -271 M 13.2 M 67.8 M -362 M -170 M 168 M 207 M - - - - -

Revenue

2.39 B 2.21 B 2.09 B 1.99 B 1.63 B 1.66 B 1.03 B 1.02 B - - - - -

Cost of Revenue

1.57 B 1.43 B 1.32 B 1.33 B 1.15 B 939 M 507 M 421 M - - - - -

Gross Profit

821 M 785 M 769 M 628 M 353 M 716 M 526 M 597 M - - - - -

Operating Income

204 M -94.9 M 153 M 91.2 M -249 M -19.7 M 245 M 285 M - - - - -

Interest Expense

5.12 M 17.8 M 15.3 M 2.59 M 1.46 M 1.18 M -47 K -669 K - - - - -

EBITDA

271 M -26.8 M 213 M 152 M 21.7 M 374 M 271 M 307 M - - - - -

Operating Expenses

- - - - 539 M 480 M 301 M 324 M - - - - -

General and Administrative Expenses

430 M 400 M 366 M 327 M 290 M 230 M 109 M 119 M - - - - -

All numbers in USD currency

Quarterly Income Statement Amneal Pharmaceuticals

2024-Q1 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

307 M 154 M 152 M - 151 M 151 M 150 M - 149 M 149 M 148 M - 148 M 147 M 147 M - 131 M 128 M 128 M - 127 M 127 M 1 K 1 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-91.6 M 22.2 M -6.94 M - -7.61 M -242 M -8.82 M - -7.78 M 30 M 12.7 M - -21.6 M -24.2 M 120 M -64.9 M -265 M -16.9 M -47.9 M -20.3 M 6.89 M -17.9 M - - - - 42.3 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

659 M 599 M 558 M - 546 M 559 M 498 M - 529 M 535 M 493 M - 519 M 465 M 499 M 397 M 378 M 405 M 446 M 498 M 476 M 414 M - - 255 M 260 M 226 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

421 M 379 M 379 M - 351 M 359 M 323 M - 329 M 323 M 302 M - 353 M 320 M 314 M - 268 M 296 M 310 M - 269 M 235 M 131 M - 120 M 136 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

238 M 220 M 178 M - 194 M 201 M 175 M - 199 M 212 M 192 M - 134 M 144 M 183 M 110 M 54.4 M 105 M 83.1 M 193 M 200 M 178 M 145 M 151 M 135 M 124 M 116 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-10.7 M 80.1 M 34.4 M - 44.4 M -199 M 23.3 M - 28.5 M 67.1 M 45.9 M - 2.44 M 10.8 M 57.8 M - -112 M -18.9 M -94.4 M - 74.6 M -181 M 63.6 M - 78.8 M 44.6 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

4.07 M 12 K 4.36 M - 5.71 M 6.94 M 2.12 M - 3.87 M 4.03 M 794 K - 898 K 571 K 633 K - 446 K 149 K 1.11 M - -1.01 M 791 K 948 K - -93 K -78 K - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

29.2 M 121 M 75.5 M - 88.9 M -157 M 64.2 M - 72.3 M 111 M 87.6 M - 47 M 54.7 M 100 M - -74.3 M 15.9 M -63.4 M - 91.9 M -166 M 65.3 M - 89.4 M 54.3 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

113 M 106 M 102 M - 100 M 98.8 M 98.7 M - 91.4 M 86.2 M 90.7 M - 83.1 M 80.9 M 78 M - 63.8 M 67.3 M 84.4 M - 75.5 M 56 M 25.1 M - 27.4 M 26.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency